Interestingly, PAFR activation was found to reduce the cytotoxic effects of targeted therapy; however, the PAFR antagonist and miR-149-5p overexpression exerted no effects on targeted therapy-mediated decreased proliferation of NSCLC cells. The gene discussed is PTAFR; the disease is non-small cell lung carcinoma.